Literature DB >> 22337789

Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis.

Steffen Moritz1, Jerome Favrod, Christina Andreou, Anthony P Morrison, Francesca Bohn, Ruth Veckenstedt, Peter Tonn, Anne Karow.   

Abstract

Antipsychotic medication represents the treatment of choice in psychosis according to clinical guidelines. Nevertheless, studies show that half to almost three-quarter of all patients discontinue medication with antipsychotics after some time, a fact which is traditionally ascribed to side-effects, mistrust against the clinician and poor illness insight. The present study investigated whether positive attitudes toward psychotic symptoms (ie, gain from illness) represent a further factor for medication noncompliance. An anonymous online survey was set up in order to prevent conservative response biases that likely emerge in a clinical setting. Following an iterative selection process, data from a total of 113 patients with a likely diagnosis of schizophrenia and a history of antipsychotic treatment were retained for the final analyses (80%). While side-effect profile and mistrust emerged as the most frequent reasons for drug discontinuation, 28% of the sample reported gain from illness (eg, missing voices, feeling of power) as a motive for noncompliance. At least every fourth patient reported the following reasons: stigma (31%), mistrust against the physician/therapist (31%), and rejection of medication in general (28%). Approximately every fifth patient had discontinued antipsychotic treatment because of forgetfulness. On average, patients provided 4 different explanations for noncompliance. Ambivalence toward symptoms and treatment should thoroughly be considered when planning treatment in psychosis. While antipsychotic medication represents the evidence-based cornerstone of the current treatment in schizophrenia, further research is needed on nonpharmacological interventions for noncompliant patients who are willing to undergo intervention but refuse pharmacotherapy.

Entities:  

Keywords:  adherence; antipsychotics; compliance; neuroleptics; psychosis; schizophrenia

Mesh:

Substances:

Year:  2012        PMID: 22337789      PMCID: PMC3686441          DOI: 10.1093/schbul/sbs005

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  32 in total

1.  The omnipotence of voices. II: The Beliefs About Voices Questionnaire (BAVQ).

Authors:  P Chadwick; M Birchwood
Journal:  Br J Psychiatry       Date:  1995-06       Impact factor: 9.319

2.  A virtual reality apartment as a measure of medication management skills in patients with schizophrenia: a pilot study.

Authors:  Matthew M Kurtz; Elizabeth Baker; Godfrey D Pearlson; Robert S Astur
Journal:  Schizophr Bull       Date:  2006-09-06       Impact factor: 9.306

3.  The omnipotence of voices. A cognitive approach to auditory hallucinations.

Authors:  P Chadwick; M Birchwood
Journal:  Br J Psychiatry       Date:  1994-02       Impact factor: 9.319

4.  Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.

Authors:  Anne Karow; Joerg Czekalla; Ralf W Dittmann; Alexander Schacht; Thomas Wagner; Martin Lambert; Benno G Schimmelmann; Dieter Naber
Journal:  J Clin Psychiatry       Date:  2007-01       Impact factor: 4.384

5.  How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up.

Authors:  Martin Harrow; Thomas H Jobe
Journal:  Schizophr Bull       Date:  2008-07-09       Impact factor: 9.306

6.  Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.

Authors:  Anita Holzinger; Watter Loffler; Peter Muller; Stefan Priebe; Matthias C Angermeyer
Journal:  J Nerv Ment Dis       Date:  2002-09       Impact factor: 2.254

7.  Positive and useful auditory vocal hallucinations: prevalence, characteristics, attributions, and implications for treatment.

Authors:  J A Jenner; S Rutten; J Beuckens; N Boonstra; S Sytema
Journal:  Acta Psychiatr Scand       Date:  2008-07-10       Impact factor: 6.392

8.  Cognitive and emotional predictors of predisposition to hallucinations in non-patients.

Authors:  Anthony P Morrison; Adrian Wells; Sarah Nothard
Journal:  Br J Clin Psychol       Date:  2002-09

Review 9.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Authors:  S Leucht; D Arbter; R R Engel; W Kissling; J M Davis
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

10.  Predictors of compliance with lithium and carbamazepine regimens in the long-term treatment of recurrent mood and related psychotic disorders.

Authors:  A Lenzi; F Lazzerini; G F Placidi; G B Cassano; H S Akiskal
Journal:  Pharmacopsychiatry       Date:  1989-01       Impact factor: 5.788

View more
  23 in total

1.  Insight, positive and negative symptoms, hope, depression and self-stigma: a comprehensive model of mutual influences in schizophrenia spectrum disorders.

Authors:  B Schrank; M Amering; A Grant Hay; M Weber; I Sibitz
Journal:  Epidemiol Psychiatr Sci       Date:  2013-07-24       Impact factor: 6.892

2.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

3.  The customer is always right? Subjective target symptoms and treatment preferences in patients with psychosis.

Authors:  Steffen Moritz; Fabrice Berna; Susanne Jaeger; Stefan Westermann; Matthias Nagel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-05-18       Impact factor: 5.270

4.  Embracing Psychosis: A Cognitive Insight Intervention Improves Personal Narratives and Meaning-Making in Patients With Schizophrenia.

Authors:  Steffen Moritz; Candelaria I Mahlke; Stefan Westermann; Friederike Ruppelt; Paul H Lysaker; Thomas Bock; Christina Andreou
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

5.  Analysis of Medication Adherence and Its Influencing Factors in Patients with Schizophrenia in the Chinese Institutional Environment.

Authors:  Wei Yu; Jie Tong; Xirong Sun; Fazhan Chen; Jie Zhang; Yu Pei; Tingting Zhang; Jiechun Zhang; Binggen Zhu
Journal:  Int J Environ Res Public Health       Date:  2021-04-29       Impact factor: 3.390

6.  French version validation of the psychotic symptom rating scales (PSYRATS) for outpatients with persistent psychotic symptoms.

Authors:  Jerome Favrod; Shyhrete Rexhaj; Pascale Ferrari; Sabrina Bardy; Claude Hayoz; Stéphane Morandi; Charles Bonsack; Fabienne Giuliani
Journal:  BMC Psychiatry       Date:  2012-09-28       Impact factor: 3.630

Review 7.  Strategies to improve medication adherence in patients with schizophrenia: the role of support services.

Authors:  Peggy El-Mallakh; Jan Findlay
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-16       Impact factor: 2.570

8.  Self-disorders and schizophrenia: a phenomenological reappraisal of poor insight and noncompliance.

Authors:  Mads G Henriksen; Josef Parnas
Journal:  Schizophr Bull       Date:  2013-06-24       Impact factor: 9.306

9.  Metacognition-augmented cognitive remediation training reduces jumping to conclusions and overconfidence but not neurocognitive deficits in psychosis.

Authors:  Steffen Moritz; Teresa Thoering; Simone Kühn; Bastian Willenborg; Stefan Westermann; Matthias Nagel
Journal:  Front Psychol       Date:  2015-08-03

10.  Can we trust the internet to measure psychotic symptoms?

Authors:  Steffen Moritz; Niels Van Quaquebeke; Tania M Lincoln; Ulf Köther; Christina Andreou
Journal:  Schizophr Res Treatment       Date:  2013-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.